NCT00437307View on ClinicalTrials.gov

Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse

PHASE3CompletedINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2013

Study Completion Date

June 30, 2015

Conditions
Ovarian Cancer
Interventions
DRUG

Topotecan

Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d

Trial Locations (1)

13353

Charité Campus Virchow Klinikum, Berlin

All Listed Sponsors
lead

North Eastern German Society of Gynaecological Oncology

OTHER

NCT00437307 - Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse | Biotech Hunter | Biotech Hunter